Hemophilia A and B

Hematology

35+ Years Treating Hemophilia

CSL Behring has over 35 years of experience in the field of hematology. From disorders that span the coagulation cascade to the management of urgent reversal of acquired bleeding, CSL Behring continues to invest in this area and remains committed to continuing our innovations in this field.

Disease States	Educational Materials	Key Publications	CSL Hematology Products	Pipeline

Hemophilia A and B

4 Hemophilia Disease State Text Boxes with the word Hemophilia in the center

image of inheritance chart with one male, female, and four children vectors

Hemophilia is a predominately male, X-linked genetic disorder.

Inherited or spontaneous mutations in the F8 (hemophilia A) or F9 (hemophilia B) gene result in a deficiency or absence of functional coagulation factor VIII (FVIII) or coagulation factor IX (FIX), respectively.

70% of hemophilia patients inherit the faulty gene; however, 30% are spontaneous and occur in patients with no family history of the disease.

The majority of carriers (XX) are asymptomatic.

Hemophilia A

Estimated prevalence at birth is 24.6 cases per 100,000 males for all severities of hemophilia A (9.5 cases for severe hemophilia A).

Hemophilia B

Estimated prevalence at birth is 5.0 cases per 100,000 males for all severities of hemophilia B (1.5 cases for severe hemophilia B).

Image of diagnosis chart for FVIII deficiency or FIX deficiency

Mild

>5% - 40% of Normal Activity Levels

Spontaneous bleeding is rare
Often diagnosed late
Severe bleeding with major trauma or surgery

Moderate

1% - ≤5% of Normal Factor Activity Levels

Occasional spontaneous bleeding
Bleeding into joints and muscles after minor injuries
Excessive/prolonged bleeding after minor injuries, surgeries, or trauma

Severe

<1% of Normal Factor Activity Levels

Frequent spontaneous bleeding (~2-5 per month)
Spontaneous bleeds into joints and soft tissues
Excessive/prolonged bleeding after minor injuries, surgeries, trauma, or dental work

Images of healthy joints and then joints that are affected by having Hemophilia, and a chart that shows the annual number of joint bleeds adcording to FVIII activity

Joint bleeds account for 70-80% of bleeds in patients with hemophilia.

As little as one joint bleed can lead to irreversible joint damage.

Prophylaxis initiated prior to the onset of arthropathy has been shown to preserve joint function in adulthood.

High trough levels are important to prevent bleeds and protect joints; in patients with hemophilia A, those with low factor levels (<5%) have the highest risk for joint bleeds, while those with factor levels of ≥15% had a very low risk approximating no expected joint bleeds.

Hemophilia A
FVIII concentrates are the treatment of choice.
Each unit of FVIII/kg infused will raise the plasma FVIII level approximately 2 IU/dL.
Desmopressin (DDAVP) may be utilized in patients with mild or moderate disease.
Individual response should be tested prior to therapeutic use (significant differences between individuals).

Hemophilia B
FIX concentrates are the treatment of choice.
The use of pure FIX concentrates is preferable for treatment over PCC.
Each unit of FIX/kg infused will raise the plasma FIX level approximately 1 IU/dL.

Category Treatment

On Demand Episodic replacement therapy given at the time of clinically evident bleeding

Prophylaxis Continuous/regular replacement therapy given to avoid bleeding

Prevention Replacement therapy given to prevent bleeding for certain high risk periods (eg, surgery)

Treatment Guidelines

World Federation of Hemophilia Guidelines for the Management of Hemophilia